Augmentin Dosing for Recurrent Acute Otitis Media
For recurrent acute otitis media in children, use high-dose amoxicillin-clavulanate (Augmentin ES-600) at 90 mg/kg/day of the amoxicillin component divided into two doses for 10 days. 1
FDA-Approved Indication and Dosing
Augmentin ES-600 is specifically FDA-approved for recurrent or persistent acute otitis media in pediatric patients with defined risk factors 1:
- Antibiotic exposure for AOM within the preceding 3 months, AND
- Age ≤ 2 years OR daycare attendance 1
The formulation provides 90 mg/kg/day amoxicillin with 6.4 mg/kg/day clavulanate, divided every 12 hours 1
Treatment Duration by Age
Duration should be tailored to the child's age 2:
- Children < 2 years: 10-day course (standard recommendation) 2
- Children 2-5 years: 7-day course is equally effective for mild-moderate AOM 2
- Children ≥ 6 years: 10-day course for mild-moderate AOM 2
- All children with severe symptoms: 10-day course regardless of age 2
Clinical Efficacy Evidence
The high-dose formulation demonstrates superior outcomes for resistant pathogens 1:
- 98.4% bacteriologic eradication for all S. pneumoniae strains 1
- 100% eradication for S. pneumoniae with penicillin MIC = 2 mcg/mL 1
- 85.7% eradication for S. pneumoniae with penicillin MIC = 4 mcg/mL 1
- 89.1% clinical success at 2-4 days post-therapy 1
A comparative trial showed Augmentin ES-600 superior to standard-dose cefdinir (85% vs 70% clinical cure, P < 0.01) 3
Rationale for High-Dose Regimen
The 90/6.4 mg/kg/day formulation addresses specific clinical needs 1, 4:
- Provides adequate coverage for penicillin-intermediate and resistant S. pneumoniae (MIC ≤ 2 mcg/mL) 1
- Covers β-lactamase-producing H. influenzae and M. catarrhalis 1
- Maintains the same clavulanate dose as standard formulations while doubling amoxicillin, creating a 14:1 ratio 5
Important caveat: This formulation is NOT indicated for S. pneumoniae with penicillin MIC ≥ 4 mcg/mL 1
Safety Profile
Tolerability is comparable to standard-dose formulations 1:
- Protocol-defined diarrhea: 11-13% (similar to standard dose at 9.4%) 1
- Most common adverse events: vomiting (6.9%), fever (6.1%), diaper rash (6.1%) 1
- Only 2 patients discontinued due to diarrhea in clinical trials 1
Recent evidence suggests even lower clavulanate concentrations (80/2.85 mg/kg/day) may reduce diarrhea (17% vs 26%) and diaper dermatitis (21% vs 33%) without compromising efficacy 6, though this is not yet FDA-approved.
Alternative Management Considerations
For children meeting criteria for recurrent AOM (≥3 episodes in 6 months or ≥4 episodes in 12 months with ≥1 in past 6 months) 2:
Antibiotic prophylaxis is NOT recommended 2:
- Provides only modest benefit (1 child per year prevented per treatment) 2
- Benefits cease after stopping prophylaxis 2
- Contributes to antibiotic resistance 2
Tympanostomy tubes are an option for severe recurrent cases 2:
- Reduces AOM episodes by 1.5 in 6 months post-surgery 2
- Improves quality-of-life measures 2
- Decision should be joint between parent and clinician 2
Common Pitfalls to Avoid
- Do not use standard-dose amoxicillin-clavulanate (45/6.4 mg/kg/day) for recurrent AOM with risk factors—this provides inadequate coverage for resistant S. pneumoniae 1
- Avoid trimethoprim-sulfamethoxazole or erythromycin-sulfisoxazole after amoxicillin failure, as resistance is substantial 2
- Do not prescribe for S. pneumoniae with penicillin MIC ≥ 4 mcg/mL—consider tympanocentesis and alternative agents 1
- Recent data shows amoxicillin alone remains effective despite β-lactamase-producing bacteria prevalence 7, 8, but for recurrent/persistent AOM specifically, the high-dose amoxicillin-clavulanate formulation is indicated per FDA labeling 1